| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Represent the value of payment of underwriters promissory note | -696 | -696 |
| Represents the amount of prepaid of issuance cost related to at the market offering | 31 | - |
| Net cash provided by (used in) financing activities | 15,861 | 7,237 |
| Cash, cash equivalents, restricted cash, and restricted cash equivalents, period increase (decrease), excluding exchange rate effect | 8,051 | 2,270 |
| Effect of exchange rate changes on cash | 3 | - |
| Cash and cash equivalents at beginning of period | 1,270 | - |
| Cash and cash equivalents at end of period | 9,324 | - |
Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp (SLXN)